Topics

LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients

2015-12-17 04:38:23 | BioPortfolio

Summary

Evaluate the proportion of patients with HCV viral replication with fixed dose combination of ledipasvir and sofosbuvir for 8 weeks and 12 weeks when initiated within the first 90 days

Evaluate the efficacy and safety of ledipasvir and sofosbuvir for 12 weeks compared to ledipasvir and sofosbuvir + ribavarin for 12 weeks when initiated > 90 days post-liver transplant

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

HCV

Intervention

Sofosbuvir/Ledipasvir, Sofosbuvir/Ledipasvir

Status

Not yet recruiting

Source

Medical University of South Carolina

Results (where available)

View Results

Links

Published on BioPortfolio: 2015-12-17T04:38:23-0500

Clinical Trials [219 Associated Clinical Trials listed on BioPortfolio]

12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

People who are infected with Hepatitis C Virus (HCV) have a great chance of being cured of the infection when they are treated with sofosbuvir. However, in some instances, treatment with s...

Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy

This is a prospective, controlled, open-label, pharmacokinetic study. This study aims at studying the PK of ledipasvir, sofosbuvir, and GS-331007 metabolite in HCV infected children with h...

Sofosbuvir+Ledipasvir ±Ribavirin and Sofosbuvir+Ribavirin for Pts With Indolent Bcell Lymphoma Associated With HCV Infection Treatment With Sofosbuvir Plus Ledipasvir ± Ribavirin(G1, 3 and 4) and Sofosbuvir+Ribavirin(G2) for Pts With Hepatitis C Virus A

This is a non-randomized, a single arm, phase II multicentre study of sofosbuvir plus ledipasvir ± ribavirin (genotype 1, 3 and 4) or sofosbuvir + ribavirin (genotype 2) for patients with...

Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection

The goals of therapy against chronic hepatitis B are to decrease the morbidity and mortality related to chronic HBV infection. Currently available antiviral therapy can suppress viral repl...

Sofosbuvir, Ledipasvir, Ribavirin for HCV Cirrhotics, Genotype 1

The investigators will treat 50 patients with cirrhosis due to hepatitis C genotype 1, with sofosbuvir 400 mg daily, ledipasvir 90 mg daily and weight-based ribavirin (1000 mg/d if 75 kg, divide...

PubMed Articles [42 Associated PubMed Articles listed on BioPortfolio]

Ledipasvir and sofosbuvir for 12 weeks for HCV genotype 2 infection: A propensity score matched analysis.

Hepatitis C virus (HCV) genotype 2 (GT2) is common in East-Asia, sub-Saharan Africa, and Latin America. However, many countries in these areas lag behind other areas of the world in government approva...

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.

Guidelines advocate the treatment of HCV in all HIV/HCV co-infected individuals. The aim of this randomized, open-label study (ClinicalTrials.gov identifier: NCT02707601; https://clinicaltrials.gov/ct...

Effects of Sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3 to 6 years of age.

Treatment of children aged 3-6 genotype-4 is still limited by the interferon side effects. We aimed in this study to evaluate the effectiveness and safety of sofosbuvir/ledipasvir in children (3-6 yea...

Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness.

Egypt has the highest prevalence of hepatitis C virus (HCV) infection. Anti-HCV antibodies were detectable in 3% of children in Upper Egypt. Our aim was to evaluate the efficacy of ledipasvir/sofosbuv...

Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.

Chronic hepatitis C (CHC) is a common progressive healthcare challenge that leads to liver cirrhosis, liver failure, and hepatocellular carcinoma. The optimum therapy was a combination of pegylated in...

Medical and Biotech [MESH] Definitions

A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.

More From BioPortfolio on "LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients"

Quick Search

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...


Searches Linking to this Trial